SGMO News and Press, Sangamo Therapeutics Inc. From 11/02/23

2023-11-02 11:51:04 ET Sangamo Therapeutics, Inc. (SGMO) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Louise Wilkie - Vice President-Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathal...

2023-11-01 16:04:56 ET More on Sangamo Therapeutics Sangamo Therapeutics: Recent Updates Bolster My Long-Term Conviction Sangamo Therapeutics, Inc. (SGMO) Q2 2023 Earnings Call Transcript Sangamo Therapeutics Q3 2023 Earnings Preview Gene editing stocks gain ...

Announced additional progress towards strategic transformation into neurology-focused genomic medicine company. Focusing resources on proprietary epigenetic regulation therapies treating neurological diseases and novel AAV capsid delivery technologies. Dosed a total of 25 patients...

Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...

Sangamo Therapeutics Inc. (SGMO) is expected to report $-0.33 for Q3 2023

2023-10-31 12:46:31 ET More on Eli Lilly Albemarle Vs. Eli Lilly: 1 Potentially Set To Soar And 1 Bubble Stock To Ignore Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated Eli Lilly: Do Not Chase This Stock Over The Cliff ...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2023 financial results after the market closes on Wednesday, November 1, 2023. The Company will hold a conference call at 8:30 a.m. ET on Thur...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Society of Gene & Cell Therapy (ESGCT) has accepted six Sangamo abstracts for presentation at the 30 th Annual Congress being held October 24-27, 2023, in-person in Brussels, Belgium. ...

2023-09-29 13:22:44 ET More on Sangamo Therapeutics Sangamo Therapeutics: Recent Updates Bolster My Long-Term Conviction Sangamo Therapeutics GAAP EPS of -$0.66 misses by $0.32, revenue of $6.84M misses by $8.49M Sangamo gains on option and license agreement with Chr...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that it will participate in the Jefferies Cell & Genetic Medicine Summit, to be held from September 26-27, 2023 in New York City. Sandy Macrae, Sangamo’s President and Chief Executive Officer is...